Ultra-Low-Dose / Microdose Lithium Literature
1 Sikorav 2026 — Ultra-Low-Dose Lithium Self-Experiment Case Report
Full Citation:: Sikorav M. Ultra-low-dose lithium citrate for recurrent brief depressive episodes with sensory hypersensitivity: a self-experiment case report. Unpublished clinical correspondence. 2026. Study Design:: n=1 self-experiment Sample Size:: 1 Dose:: Lithium citrate 2 mg/day (= 2 mg elemental lithium) Duration:: 4 months Key Findings::
- Complete remission of recurrent brief depressive episodes (3-6 days every 4-8 weeks)
- Suicidal ideation resolution
- Stress resilience improvement
- Sensory hypersensitivity remission (sound, screens, crowds)
- No side effects
- Trigger factors identified: sleep deprivation, alcohol, altitude change, seasonal (Aug fatigue)Conclusion:: Ultra-low-dose lithium citrate may produce rapid and sustained remission of depressive symptoms with sensory hypersensitivity, at doses far below conventional therapeutic range. Limitations:: n=1, self-report, no blinding, no biomarker confirmation, short follow-up (4 months), no discontinuation/rechallenge verification. Certainty Assessment::
- *Quality:* Low (self-report single case)
- *Sample:* Minimal (n=1)
- *Replication:* None
- *Score:* 0.202 Guttuso et al. 2024 — Lithium Aspartate for Long COVID (JAMA Netw Open)
Full Citation:: Guttuso T Jr, Zhu J, Wilding GE. Lithium aspartate for long COVID fatigue and cognitive dysfunction: a randomized clinical trial. JAMA Network Open. 2024;7(10):e2436874. (Guttuso, Zhu, and Wilding 2024) DOI:: 10.1001/jamanetworkopen.2024.36874 PMID:: 39356507 Study Design:: RCT, double-blind, placebo-controlled + open-label dose-finding Sample Size:: 52 (26 lithium, 26 placebo) Dose:: 10-15 mg/day (RCT); up to 45 mg/day (open-label) Key Findings::
- Negative primary outcome at 10-15 mg: Δ -3.6 (95% CI -16.6 to 9.5; p=0.59)
- Possible signal at 40-45 mg/day in n=3 dose-finding
- Serum Li levels: 0.10, 0.18, 0.49 mEq/L at higher doses
- No adverse events attributable to lithiumConclusion:: 10-15 mg/day ineffective for Long COVID fatigue; higher doses may warrant further study. Limitations:: Short follow-up (3 weeks), small sample, underpowered. Certainty Assessment::
- *Quality:* High (JAMA Network Open; rigorous RCT design)
- *Sample:* Medium (n=52)
- *Replication:* Single center not yet replicated
- *Score:* 0.753 Strawbridge et al. 2023 — Low-Dose Lithium Systematic Review (Neurosci Biobehav Rev)
Full Citation:: Strawbridge R, Kerr-Gaffney J, Bessa G, et al. Identifying the neuropsychiatric health effects of low-dose lithium interventions: a systematic review. Neuroscience and Biobehavioral Reviews. 2023;144:104975. (Strawbridge et al. 2023) DOI:: 10.1016/j.neubiorev.2022.104975 PMID:: 36436738 Study Design:: Systematic review Sample Size:: 18 articles Key Findings::
- Significant benefits for attenuating cognitive decline
- Potential as adjunctive therapy for depression/mania
- Low-dose lithium safe across all studiesConclusion:: Low-dose lithium has pro-cognitive effects and positive safety profile; further research warranted. Limitations:: Heterogeneity across studies; most not at microdose level. Certainty:: 0.85
4 Manchia et al. 2024 — Lithium and Its Effects: Does Dose Matter? (Int J Bipolar Disord)
Full Citation:: Manchia M, Paribello P, Pinna M, et al. Lithium and its effects: does dose matter? International Journal of Bipolar Disorders. 2024;12(1):23. (Manchia et al. 2024) DOI:: 10.1186/s40345-024-00345-8 PMID:: 38914810 Study Design:: Narrative review Key Findings::
- Mood stabilization maximal at >0.6 mEq/L
- Lower levels may prevent depressive recurrences in elderly
- Microdoses could decrease suicide risk
- Cognitive benefit at subtherapeutic doses
- Anti-inflammatory/neuroprotective at "several fold lower" than clinicalConclusion:: Clinical and molecular effects of lithium show dose specificity; microdose effects are biologically plausible. Limitations:: Narrative not systematic; author selection bias. Certainty:: 0.80
5 Toricelli et al. 2021 — Microdose Lithium Reduces Neuroinflammation (Cell Mol Neurobiol)
Full Citation:: Toricelli M, Evangelista SR, Buck HS, Viel TA. Microdose lithium treatment reduced inflammatory factors and neurodegeneration in organotypic hippocampal culture of old SAMP-8 mice. Cellular and Molecular Neurobiology. 2021;41(7):1509-1520. (Toricelli et al. 2021) DOI:: 10.1007/s10571-020-00916-0 PMID:: 32642922 Study Design:: Preclinical, ex vivo organotypic hippocampal culture Key Findings::
- 2 µM Li₂CO₃: Reduced cell death in CA2
- 20 µM: Neuroprotection in CA3/GrDG; IL-1α, IL-6, CCL-4 reduced; IL-10 increased; NFkB reduced
- 200 µM: Toxic — increased cell death
- Bimodal dose-response: neuroprotection + anti-inflammation at microdose; toxicity at high doseConclusion:: Very low lithium doses reduce neuronal loss and neuroinflammation in aged hippocampus. Limitations:: Ex vivo model; murine; not translated to humans. Certainty:: 0.50
6 Nunes et al. 2013 — Microdose Lithium in Alzheimer’s Disease (Curr Alzheimer Res)
Full Citation:: Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Current Alzheimer Research. 2013;10(1):104-107. (Nunes, Viel, and Buck 2013) DOI:: 10.2174/1567205011310010014 PMID:: 22746245 Study Design:: Double-blind RCT Dose:: 300 µg/day lithium chloride Key Finding:: Treated group showed no MMSE decline vs progressive decline in controls. Limitations:: Very small sample, partial blinding concerns. Certainty:: 0.35
7 Forlenza et al. 2011 — Lithium for Amnestic MCI (Br J Psychiatry)
Full Citation:: Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. British Journal of Psychiatry. 2011;198(5):351-356. (Forlenza et al. 2011) DOI:: 10.1192/bjp.bp.110.080044 PMID:: 21525519 Study Design:: RCT, double-blind, 12 months (n=45) Target serum:: 0.25-0.5 mmol/L (substandard) Key Findings::
- Decreased CSF P-tau (p=0.03)
- Better cognitive performance (ADAS-Cog, attention tasks)Conclusion:: Lithium has disease-modifying properties at below-standard serum levels. Limitations:: Small sample, single center. Certainty:: 0.70
8 Barjasteh-Askari et al. 2020 — Lithium in Water and Suicide Meta-Analysis (J Affect Disord)
Full Citation:: Barjasteh-Askari F, Davoudi M, Amini H, et al. Relationship between suicide mortality and lithium in drinking water: a systematic review and meta-analysis. Journal of Affective Disorders. 2020;264:234-241. (Barjasteh-Askari et al. 2020) DOI:: 10.1016/j.jad.2019.12.027 PMID:: 32056756 Key Finding:: OR 0.76 (95% CI 0.66-0.87) for suicide in areas with higher water lithium. Limitations:: Ecological design, no individual-level data. Certainty:: 0.70
9 Mauer et al. 2014 — Standard and Trace-Dose Lithium Systematic Review (Aust N Z J Psychiatry)
Full Citation:: Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits. Australian and New Zealand Journal of Psychiatry. 2014;48(9):809-818. (Mauer, Vergne, and Ghaemi 2014) DOI:: 10.1177/0004867414536932 PMID:: 24919696 Key Findings::
- 9/11 ecological: trace Li in water associated with lower suicide/homicide
- 4/4 small RCTs showed benefit of Li in AD
- Trace Li RCT showed mood benefitLimitations:: Ecological studies cannot establish causation. Certainty:: 0.70
Full Citation:: Issa A, Lin J-M S, Chen Y, Attell J, Brimmer D, Bertolli J, Natelson BH, Lapp CW, Podell RN, Kogelnik AM, Klimas NG, Peterson DL, Bateman L, Unger ER; MCAM Study Group. “Autonomic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Findings from the Multi-Site Clinical Assessment of ME/CFS (MCAM) Study in the USA.” Journal of Clinical Medicine. 2025;14(17):6269. DOI:: 10.3390/jcm14176269 PMID:: 40944028 Study Design:: Multi-site cross-sectional study; n=442 (301 ME/CFS, 141 healthy controls); 7 specialist ME/CFS clinics across the USA. Tools: COMPASS-31 (Composite Autonomic Symptom Scale 31), NASA lean test, medical history review. Key Findings::
- 97% of ME/CFS participants had at least one autonomic symptom (vs.\ controls, all $p$\<0.0001)
- Higher burden across all three assessment tools: COMPASS-31, NASA lean test, medical history
- Orthostatic intolerance, gastrointestinal, and pupillomotor domain symptoms correlated with heightened illness severity
- Supports targeted dysautonomia assessment to guide symptom managementConclusion:: The largest multi-site US study of autonomic dysfunction in ME/CFS to date. The near-universal (97%) prevalence of autonomic symptoms, objectively confirmed by NASA lean test and COMPASS-31, provides high-quality evidence that dysautonomia is a core feature rather than an epiphenomenon of ME/CFS. The severity correlation with orthostatic intolerance domains is clinically actionable. Limitations:: Cross-sectional design precludes causal inference; specialist clinic sample (selection bias toward more severe or diagnosed patients); no longitudinal follow-up Certainty:: 0.75
10 Goicoechea-Calvo et al. 2026 — Pediatric Pulmonary Rehabilitation in Post-COVID-19
(Goicoechea-Calvo et al. 2026)
Full Citation:: Goicoechea-Calvo A, Navarro Expósito N, Coll-Fernández R, Colomer Giralt M, Martín Saavedra A, González-Aumatell A, Méndez-Hernández M, Carreras-Abad C, Moreira M, Giralt-López M, Pallarès N, Tebe Cordomi C, Rodríguez-Palmero A, Rodrigo C, Durà Mata MJ. “Impact of Pulmonary Rehabilitation on Physical, Mental Health and Quality of Life in Children with Post-COVID-19 Condition: A 12-Month Quasi-Experimental Study.” Journal of Clinical Medicine. 2026;15(2):535. DOI:: 10.3390/jcm15020535 PMID:: 41598473 Study Design:: Quasi-experimental (pre-post) study; n=115 pediatric post-COVID patients; mean age 13.3 years; 66.1% female; 12-month multidisciplinary pulmonary rehabilitation program. Spain. Key Findings::
- 6-minute walk distance improved +37 m (509 to 546 m; $p$\<0.001; Cohen's d=0.50)
- Handgrip strength improved +2.4 kg; breathing muscle strength +15 cmH~2~O
- Fatigue scores improved by 9.3 points
- Psychiatric symptom scores decreased by 4.5 points ($p$\<0.001)
- Overall well-being scores increased by 11 points
- Muscle imaging showed increased thickness and improved compositionConclusion:: Multidisciplinary pulmonary rehabilitation appears feasible and potentially effective for pediatric post-COVID patients. However, this is a quasi-experimental design without a control group, meaning improvements could reflect natural recovery, regression to the mean, or placebo effects in addition to any genuine rehabilitation benefit. The pediatric post-COVID population overlaps substantially with pediatric ME/CFS but is not identical. Limitations:: No control group (quasi-experimental); cannot exclude natural recovery; single center (Spain); diagnostic heterogeneity in “post-COVID” cohort; no PEM screening; no washout; 12 months may include spontaneous recovery trajectory Certainty:: 0.50
11 Vink & Vink-Niese 2026 — An Overview of Severe Myalgic Encephalomyelitis
Full Citation:: Vink M, Vink-Niese A. “An Overview of Severe Myalgic Encephalomyelitis.” Journal of Clinical Medicine. 2026;15(2):805. DOI:: 10.3390/jcm15020805 PMID:: 41598742 Study Design:: Narrative review. Authors previously published critiques of GET/CBT trial methodology (Healthcare 2022, other venues). Key Findings::
- Severe ME/CFS diagnosed clinically; no diagnostic test exists
- Most severe cases: bedbound 24/7, dependent on carers, require dark/quiet environments
- Some patients require tube feeding due to life-threatening nutritional deficiency
- 2-day CPET (cardiopulmonary exercise testing) can document abnormal exercise response for research/disability purposes
- COVID-19 has substantially increased the pool of post-infectious ME/CFS cases
- No effective treatments currently available for severe ME/CFS
- Authors call for pharmacological intervention research using advanced medical technologiesConclusion:: Provides a comprehensive narrative overview of the most severely affected ME/CFS subgroup, who are largely invisible in clinical research due to inability to participate. The Vink authorship brings specific methodological critique expertise (prior publications on GET/PACE trial flaws). The paper underscores that severe ME/CFS represents an unmet need distinct from milder presentations that dominate trial populations. Limitations:: Narrative review (not systematic); potential author perspective bias given prior advocacy positions; no new primary data; severity definitions not uniformly operationalized across cited studies Certainty:: 0.60
12 Blitshteyn 2026 — POTS, Menopause, and Hormone Replacement Therapy
Full Citation:: Blitshteyn S. “Postural Orthostatic Tachycardia Syndrome, Menopause and Hormone Replacement Therapy: Clinical Decisions in Times of Uncertainty.” Journal of Clinical Medicine. 2026;15(4):1477. DOI:: 10.3390/jcm15041477 PMID:: 41753164 Study Design:: Narrative review. Author is guest editor of this JCM special issue on infection-associated chronic conditions. Affiliation: Department of Neurology, University at Buffalo; Dysautonomia Clinic, Williamsville NY. Key Findings::
- POTS predominantly affects women of reproductive age (≥30 bpm HR rise supine to standing, without orthostatic hypotension)
- Hormonal factors significantly modulate POTS: symptoms exacerbated during menstruation; pregnancy is a recognized trigger
- For women with significant menopausal symptoms and/or POTS exacerbation in peri-/postmenopause, HRT may be considered
- Vaginal estrogen appears to be the safest option; transdermal estrogen + micronized progesterone may address menopausal symptoms
- Long-term outcomes of HRT in POTS patients remain unknownConclusion:: Addresses a clinically important gap: the management of POTS through the menopausal transition, where hormonal changes may worsen dysautonomia. The review is practical and appropriately cautious given sparse RCT evidence. Relevant for the ME/CFS population because a substantial subset has comorbid POTS, and sex-based differences in ME/CFS prevalence and presentation may partly relate to hormonal factors. Limitations:: Narrative review without systematic search; no RCT evidence for HRT in POTS specifically; author is a POTS specialist (potential perspective bias); limited generalizability to non-menopausal POTS Certainty:: 0.45
13 Boris 2026 — Telemedicine Clinic for Pediatric and Young Adult POTS
Full Citation:: Boris JR. “Patient Characteristics of a Telemedicine Clinic for Pediatric and Young Adult Postural Orthostatic Tachycardia Syndrome.” Journal of Clinical Medicine. 2026;15(4):1626. DOI:: 10.3390/jcm15041626 PMID:: 41753313 Study Design:: Retrospective analysis; n=277 adolescents and young adults with POTS; telemedicine clinic; median age 16.8 years; 88.1% female. Key Findings::
- Suspected mast cell activation syndrome (MCAS) in 70% of cases
- Joint hypermobility in 78.3% (more prevalent in females); consistent with hypermobile EDS overlap
- Migraine in 51.6%; tension-type headache in 57.4%
- Head trauma or concussion history in ~40%
- Vestibular dysfunction and convergence disorder identified as previously underrecognized comorbidities
- Telemedicine format shown feasible for comprehensive POTS evaluationConclusion:: Largest pediatric/young adult telemedicine POTS cohort to date. The high prevalence of MCAS (70%), joint hypermobility (78.3%), and neurological comorbidities (migraine, vestibular, convergence) in this cohort aligns with the emerging “dysautonomia triad” framework linking POTS, MCAS, and hypermobile connective tissue disorders. The concussion history finding (40%) raises questions about head trauma as a precipitant or comorbidity. Telemedicine feasibility is relevant for the severely affected ME/CFS subgroup. Limitations:: Retrospective single-center; telemedicine selection bias (patients able to attend video appointments); MCAS diagnosis based on suspicion rather than formal criteria in most cases; no ME/CFS diagnostic assessment performed Certainty:: 0.55